Say Hello to BrainGuide
Our new platform BrainGuide™ was featured on Good Morning America. It empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.
Aducanumab and UsAgainstAlzheimer's
Aducanumab is a proposed treatment for early Alzheimer’s disease that is intended to slow the progression of the disease. UsAgainstAlzheimer’s (UsA2) has urged the U.S. Food and Drug Administration to approve aducanumab.
UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms
New survey results from UsAgainstAlzheimer’s A-LIST shows that patients want FDA to weigh willingness of people with MCI/mild Alzheimer’s to take a disease-modifying therapy.
Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers
The Paid Leave Alliance for Dementia Caregivers commends the Biden-Harris for making support for working families a top priority in its $1.9 trillion COVID-19 economic relief proposal but urges the administration to clarify how the proposal's paid leave expansions will cover Americans who care for older adults.
UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health
UsAgainstAlzheimer’s commends Apple and Biogen for their investment in brain health research and working towards creating innovative technologies that would allow consumers to be more aware and in control of their brain health.
Say Hello to BrainGuide
Aducanumab and UsAgainstAlzheimer's
UsAgainstAlzheimer’s Survey Shows Alzheimer’s Patients Value a New Therapy that Slows Progression of Symptoms
Paid Leave Alliance for Dementia Caregivers Applauds American Rescue Plan but Urges Action on Paid Leave Support for Caregivers
UsAgainstAlzheimer’s Commends Apple and Biogen for New Research on Monitoring Brain Health

UsAgainstAlzheimer's: Working to End Alzheimer's Disease
The Alzheimer’s pandemic is the health and social economic crisis of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.
UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.
We bring all of “Us” together to:
- Advocate for increased research spending that will speed treatments to market
- Improve brain health and promote earlier detection, diagnosis and intervention
- Champion health equity and access for communities of color and women who are disproportionately impacted by the disease
- Drive changes that matter most to people living with the disease
In the past decade, progress has been made, with more hope on the horizon now than ever before.
But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.